Antigen-tailored therapy based on the inflammatory theory of atherosclerosis

References

• Ross R. Atherosclerosis — an inflammatory condition. N Engl. J. Med. 340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl. J. Med. 336,973–979 (1997).
   PubMed Web of Science ®Google Scholar
• Rader D. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA 290,2322–2324 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson G, Libby P, Schonbeck U et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91,281–291 (2002).
   PubMed Web of Science ®Google Scholar
• Capron L. Chlamydia in coronary plaques-hidden culprits or harmless hobo? Nature Med. 8,856–857 (1996).
   Google Scholar
• Libby P, Egan D, Scarlatos S. Roles of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for future research. Circulation 96,4095–4103 (1997).
   Google Scholar
• Spence JD, Norris J. Infection, inflammation, and atherosclerosis. Stroke 34,333–334 (2003).
   PubMed Web of Science ®Google Scholar
• Pasceri V, Cammarota G, Patti G et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 97,1675–1679 (1998).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Liuzzo G, Pelliccioni S et al. Combined role of the Lewis antigenic system, Chlamydia pneumoniae, and C-reactive protein in unstable angina. J Am. Coll. Cardiol 41,546–550 (2003).
   PubMed Web of Science ®Google Scholar
• Muhlestein JB. Antibiotic treatment of atherosclerosis. CUIT: Opin. Lipidol 14, 605–614 (2003).
   Google Scholar
• Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein-E-deficient mice created by homologous recombination in ES cells. Cell 71,343–353 (1992).
   PubMed Web of Science ®Google Scholar
• • Reports the creation of a murine model that develops atherosclerosis spontaneously. This model has become the reference experimental model for studying atherosclerosis.
   Google Scholar
• Rosenfeld ME, Carson KG, Johnson JL et al. Animal models of spontaneous plaque rupture: the holy grail of experimental atherosclerosis research. CUIT: Atheroscler. Rep. 4,238–242 (2002).
   Google Scholar
• Ishibashi S, Brown MS, Goldstein JL et al. Hypercholesterolemia in LDL receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92,883–893 (1993).
   PubMed Web of Science ®Google Scholar
• • Describes an additional murine model that develops significant lesions only when fed a high-fat diet.
   Google Scholar
• Palinski W, Ord VA, Plump AS et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14, 605–616 (1994).
   Google Scholar
• Roselaar SE, Kakkanathu PX, Daugherty A. Lymphocyte populations in atherosclerotic lesions of apoE -/- and LDL receptor -/- mice; decreasing density with disease progression. Arterioscler. Thromb. Vasc. Biol. 16,1013–1018 (1996).
   Google Scholar
• Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today16,27–33 (1995).
   PubMedGoogle Scholar
• Hansson GK. Inflammation and immune response in atherosclerosis. Curl: Atheroscler. Rep. 1,150–155 (1999).
   Google Scholar
• Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Ann. Rev Immunol 22, 361–403 (2004).
   PubMed Web of Science ®Google Scholar
• • Summarizes pioneering work demonstrating the relationship between the autoimmune response to heat shock protein and atherosclerosis.
   Google Scholar
• Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 23,281–291 (2002).
   Google Scholar
• Witztum J, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. Clin. Invest. 88,1785–1792 (1991).
   Google Scholar
• Biasucci LM, Liuzzo G, Ciervo A et al. Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation 107, 3015–3017 (2003).
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Vallejo AN, Kopecky SL et al. Molecular fingerprint of interferon-y signaling in unstable angina. Circulation 103, 1509–1514 (2001).
   PubMed Web of Science ®Google Scholar
• Palinski W, Rosenfeld ME, YIa-Herttuala S et al. Low-density lipoprotein undergoes oxidative modification in vivo. Proc. Natl Acad. Sci. USA 86,1372–1376 (1989).
   PubMed Web of Science ®Google Scholar
• Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl Acad. Sci. USA 85,2805–2809 (1988).
   Google Scholar
• Schafer-Elinder L, Hedin U, Dumitrescu A et al. Presence of different isoforms of phospholipase A2 in tissue slices from atherosclerotic carotid plaque. Arteriscler. Thromb. Vase. Biol. 17,2257-2263 (1997).
   Google Scholar
• Berliner JA, Territo MC, Sevanian A et al. Minimaly modified LDL stimulates monocyte endothelial interactions. J Clin. Invest. 85,1260–1266 (1990).
   PubMed Web of Science ®Google Scholar
• • Reports the functional properties of oxidized (ox) low-density lipoprotein (LDL) that are relevant to its role as a triggering agent in atherosclerosis in vivo.
   Google Scholar
• McMurray HF, Parthasarathy HF, Steinberg D. Oxidatively modified low-density lipoprotein is a chemoreactant for human T-lymphocytes. j Clin. Invest. 92, 1004–1008 (1993).
   Google Scholar
• Cushing SD, Berliner AJ, Valente MC et al. Minimally modified LDL induces monocyte chemotactic factor 1 in human endothelial and smooth muscle cells. Proc. Natl Acad. Sci. USA 87,5134–5138 (1990).
   Google Scholar
• Rajavahishisth TB, Andalibi A, Territo MC. Induction of endothelial cell expression of granulocyte and macrophage colony stimulating factors by modified low-density lipoproteins. Nature 344,254–257 (1990).
   Google Scholar
• Heery JM, Kozak M, Stafforini DM et al. Oxidatively modified LDL contains phospholipids with platelet activating factor like activity and stimulates the growth of smooth muscle cells. J Clin. Invest. 96, 2322–2330 (1995).
   PubMed Web of Science ®Google Scholar
• • Demonstrates for the first time that T-cells within atherosclerotic plaques are reactive with oxLDL and exhibit a Thl phenotype.
   Google Scholar
• Stemme S, Faber B, Holm J. T-lymphocytes from human atherosclerotic plaques recognize oxidiezed low-density lipoprotein. Proc. Natl Acad. Sci. USA 92, 3893–3897 (1995).
   Google Scholar
• Bergmark C, Wu R, De Faire U et al. Patients with early onset peripheral vascular disease have increased levels of antibodies against oxidized LDL. Arterioscler. Throm. Vasc. Biol. 15, 441–445 (1995).
   Google Scholar
• Salonen JT, Yla-Herttuala S, Yamamoto R et al. Antibodies against oxidized LDL and the progression of carotid atherosclerosis. Lancet339, 883–887 (1992).
   PubMed Web of Science ®Google Scholar
• • Authors report for the first time that antibodies to oxLDL correlate with atherosclerosis in humans.
   Google Scholar
• Puurunen M, Manttari M, Manninen V et al. Antibody against oxidized LDL predicting myocardial infarction. Arch. Intern. Med. 154,2605–2609 (1994).
   PubMedGoogle Scholar
• Virella G, Virella I, Leman RB et al. Anti-oxidized LDL antibodies in patients with coronary heart disease and healthy controls. Int. J. Clin. Lab. Res. 23,95–101 (1993).
   PubMedGoogle Scholar
• Klimov AN, Denisenko AD, Popov AV et al. Lipoprotein-antibody immune complexes: their catabolism and role in foam cell formation. Atherosclerosis 58, 1–15 (1985).
   PubMed Web of Science ®Google Scholar
• Khoo JC, Miller E, Pio F et al. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggragates. Arterioscler. Thromb. 12,1258–1266 (1992).
   PubMedGoogle Scholar
• Horkko S, Bird DA, Miller E et al. Monoclonal autoantibodies specific for oxdized phopholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoprotein. J. Clin. Invest. 103,117–128 (1999).
   PubMed Web of Science ®Google Scholar
• Palinski W, Miller E, Witztum JL. Immunization of low-density lipoprotein (LDL) deficient rabbits with homologeous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl Acad. Sci. USA 92, 821–825 (1995).
   Google Scholar
• • Authors demonstrate for the first time that immunization against oxLDL reduces atherosclerotic lesions in rabbits.
   Google Scholar
• Alving CR, Swartz GM, Wassef NM et al. Immunization with cholesterol-rich liposomes induces anticholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J Lab. Clin. Med. 127,40–49 (1996).
   PubMed Web of Science ®Google Scholar
• George J, Afek A, Gilburd B et al. Hyperimmunization of apoE deficient mice with homologous MDA-low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138, 147–152 (1998).
   PubMed Web of Science ®Google Scholar
• Freigang S, Horkko S, Miller E, Witztum JL, Palinski W Immunization of LDL receptor-deficient mice with homologous malondialdehyde modified and native LDL reduces atherosclerosis progression by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arteriscler. Thromb. Vasc. Biol. 18,1972–1982 (1998).
   PubMed Web of Science ®Google Scholar
• Lindquist S, Craig EA. The heat shock proteins. Ann. Rev Genet. 22,631 (1988).
   PubMed Web of Science ®Google Scholar
• Ellis J. Proteins as molecular chaprones. Ce11328, 378 (1987).
   Google Scholar
• Jones DB, Hunter NR, Duff GW. Heat shock protein 65 as a 3-cell antigen of insulin-dependent diabetes. Lancet 336, 583 (1990).
   Google Scholar
• Winfield JB. Stress proteins, arthritis and autoimmunity. Arthritis Rheum. 32,1497 (1989).
   PubMed Web of Science ®Google Scholar
• Lai NS, Lan JL, Yu CL et al. Antibody to Mycobacterium tuberculosis 65 kDa heat shock protein in patients with rheumatoid arthritis — a survey of antigen-specific antibody isotypes and subclasses in an endemic area of previous tuberculosis infection. Ann. Rheum. Dis. 54,225-228 (1995).
   Google Scholar
• Karopoulos C, Rowley MJ, Handley CJ et al. Antibody reactivity to mycobacterial 65 kDa heat shock protein: relevance to autoimmunity. I Autoimmunity8, 235–248 (1995).
   PubMed Web of Science ®Google Scholar
• Xu Q, Dietrich H, Steiner HJ et al. Induction of arteriosclerosis in normocholesterolemic mice rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12,789-799 (1992).
   Google Scholar
• Xu Q, Kleindienst W, Waitz H et al. Increased expression of heat shock protein 65 coincides with a population of infiltrating T-lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65.1 Clin. Invest. 91,2693-2702 (1993).
   Google Scholar
• George J, Shoenfeld Y, Afek A et al. Accelerated fatty streak formation C57B116J mice by immunization with heat shock protein 65. Arterioscler. Thromb. Vag. Biol. 19,505-510 (1999).
   Google Scholar
• Afek A, George J, Gilburd B et al. Immunization with heat shock protein 65 enhances early atherosclerosis in low-density lipoprotein receptor deficient mice. Autoimmunity14, 115–121 (2000).
   Web of Science ®Google Scholar
• George J, Afek A, Gilburd B, Shoenfeld Y, Harats D. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J. Am. Coll. Cordial. 38, 900–905 (2001).
   Google Scholar
• Kandia DA, Krilis SA. (32-glycorprotein I. Lupus3, 207–212 (1994).
   Google Scholar
• Harats D, George J. CUIT: Opin. Lipid& 12,543–546 (2001).
   Google Scholar
• Galli M, Comfurius MP, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335, 1544–1547 (1990).
   PubMed Web of Science ®Google Scholar
• McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: (32GPI (apolipoprotein H). Proc. Natl Acad. Sci. USA 87,4120–4124 (1990).
   Google Scholar
• Matsuura E, Igarashi Y, Fujimoto M et al. Heterogeneity of anticardioloipin antibodies defined by the anticardiolipin cofactor. J Immunol 148,3885–3891 (1992).
   PubMed Web of Science ®Google Scholar
• Simantov R, LaSala JM, Lo SK et al. Activation of cultured endothelial cells by antiphopholipid antibodies. J Clin. Invest. 96,2211–2219 (1995).
   PubMed Web of Science ®Google Scholar
• George J, Blank M, Levy Y et al. Differential effects of anti-132GPI antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 97, 900–906 (1998).
   PubMed Web of Science ®Google Scholar
• Hasunuma Y, Matsuura E, Makita Z et al. Involvement of (32 glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol 107,569–574 (1997).
   Google Scholar
• George J, Afek A, Gilburd B et al. Induction of early atherosclerosis in LDL receptor deficient mice immunized with (32 glycoproein I. Ciruclation 15,1108–1115 (1998).
   Google Scholar
• Afek A, George J, Shoenfeld Y et al. Enhanced Atherosclerosis in ApoE deficient mice by immunization with (32-glycoprotein I. Pathobiology67,19–25 (1999).
   PubMed Web of Science ®Google Scholar
• George J, Harats D, Gilburd B et al. Immunolocalization of (32-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99,2227–2230 (1999).
   PubMed Web of Science ®Google Scholar
• George J, Afek A, Gilburd B et al. Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 6,723–729 (1997).
   PubMed Web of Science ®Google Scholar
• Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 182,207–214 (2001).
   PubMed Web of Science ®Google Scholar
• Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-B-secreting regulatory cells. Microbes Infect. 3,947–954 (2001).
   PubMed Web of Science ®Google Scholar
• Anderton SM, Wraith DC. Selection and fine-tuning of the autoimmune T-cell repertoire. Nature Rev Immunol 2, 487–498 (2002).
   PubMed Web of Science ®Google Scholar
• Weiner HL. Oral tolerance for the treatment of autoimmune diseases. Ann. Rev Med. 48,341–351 (1997).
   PubMed Web of Science ®Google Scholar
• Weiner HL, Mackin GA, Matsui M et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259,1321–1324 (1993).
   PubMed Web of Science ®Google Scholar
• • Initial attempt to apply oral tolerance as a therapeutic strategy in humans.
   Google Scholar
• Choy EH, Scott DL, Kingsley GH et al. Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum. 44,1993–1997 (2001).
   PubMed Web of Science ®Google Scholar
• Myers LK, Higgins GC, Finkel TH et al. Juvenile arthritis and autoimmunity to Type II collagen. Arthritis Rheum. 44, 1775–1781 (2001).
   PubMed Web of Science ®Google Scholar
• Maron R, Sukhova G, Faria AM et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106,1708–1715 (2002).
   PubMed Web of Science ®Google Scholar
• • Demonstrates that tolerance to heat shock protein 65 results in reduced atherosclerosis in mice.
   Google Scholar
• Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am. Coll. Cardiol 40(7), 1333–1338 (2002).
   Google Scholar
• George J, Yacov N, Breitbart E et al. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with (32-glycoprotein I. Cardiovasc. Res. 62, 603–609 (2004).
   Google Scholar